Barr Pharmaceuticals — Merger or Acquisition (July 2008)
34 slides from Barr Pharmaceuticals's merger presentation, Jul 18, 2008
Slide 1: Teva and Barr: A strategic combination
Teva and Barr A strategic combination July 18, 2008
Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication contains "forward-looking statements" which represent the current expectations and beliefs of management of Barr Pharmaceuticals, Inc. (the "Company") concerning the proposed merger of the Company with Boron Acquisition Corp., a wholly-owned subsidiary o
Slide 3: What We Will Cover
Highlights of the transaction Deal terms and process Overview of Teva What does it mean for Barr employees What We Will Cover
Slide 4: Teva Offer to Acquire Barr
Total Consideration of $7.46 billion + assumption of approx. $1.5 billion net debt Combination of cash and stock Equivalent to $66.50 per share Approved by the Board of Directors of both companies Supported by Barr's senior management team Transaction anticipated to close by end of 2008 Teva Offer t
Slide 5: Why Did Teva Choose Barr?
Our vision and success in building a highly successful specialty pharmaceutical company Why Did Teva Choose Barr? Our success in integrating the historic strengths of PLIVA into Barr Our successful management of operations in more than 30 countries Our 8,900 people of Barr who have created a success
Slide 6: A Proud and Defining Moment in Our History
A Proud and Defining Moment in Our 38 Year History Launch of generic version of Coumadin We were a pioneer in the U.S. generics industry Acquisition of Duramed Acquisition of Paragard and approval of Dual label Plan-B Historic launch of tamoxifen citrate Acquisition of PLIVA Demonstrated the value o
Slide 7: Teva's Offer Positions Us for Even Greater Growth
Teva's Offer Positions Us for Even Greater Growth Financial Strong business fundamentals in complementary geographies Exciting Global Growth Prospects both Product and Markets Generics Brands Biologics Minimal Overlap in Value and Volume Intangible World class capabilities to deliver affordable medi
Slide 8: Strategic Fit Between Barr and Teva
Strategic Fit Between Barr and Teva Biologics Management Generics IP Legislative PIV Portfolio Teva brings: Broad Line Manufacturing Significant Global Scale Neuroscience, Specialty Pharma Tax Efficiency Barr brings: Niche Products Specialty Manufacturing Eastern & Central Europe Women's Healthcare
Slide 9: Teva's growth strategy for 2008 - 2012
Teva's growth strategy for 2008 - 2012 Double the business Reach revenues of $20 billion Exceed net income margins of 20% A Strategy Driven by Growth Opportunities for Barr Even more success for our people and shareholders Combine Barr's unique capabilities and strengths with Teva's complementary st
Slide 10: Teva Strategy
Teva Strategy Increase market share in key markets Extend leadership in U.S. Establish leadership in key EU and International markets Double our product portfolio Double R&D capabilities Focus on first-to-market / Paragraph IVs Double production capacity Biotechnology: Next growth wave in generics I
Slide 11: Key Strengths
Key Strengths Growth Company Commitment to Global Generics Leadership Balanced Business Model Attractive Financial Returns Culture and Brand Largest global generic pharmaceutical company Vertically-integrated global pharmaceutical company founded in 1901 Presence in 60 countries; approximately 28,00
Slide 12: We Are Better Together
We Are Better Together Barr Teva Revenues $2.5 Billion $9.4 Billion R&D Budget $248 Million $581 Million U.S. Generic Portfolio 120 330 U.S. Proprietary Portfolio 27 3 Global Product Registrations (Pending) 700 3,000 Biopharmaceuticals Marketed 0 4 API Yes Yes Key Markets U.S., Germany, Croatia, Pol
Slide 13: Deal Terms and Process
| Deal Terms and Process Ce ey = ——! barr
Slide 14: Financial Terms of Transaction
Financial Terms of Transaction 100% of Barr shares for total cash and stock consideration of $7.46 billion Plus, assumption of net debt of $1.5 billion Each Barr share converted to $39.90 in cash and 0.6272 Teva ADRs Per share consideration equivalent to $66.50
Slide 15: Shares Vs. Stock Options/SARs
Shares Vs. Stock Options/SARs Shares (e.g., through ESPP) Each Barr share converted to $39.90 in cash and 0.6272 Teva ADRs Options (e.g., the 200 Holiday grant) Each option converted to cash (no Teva ADRs)
Slide 16: Example - Barr Stock Options/SARs
Example - Barr Stock Options/SARs Stock Options cashed out at $66.50 less Strike Price Let's say: You own 1,000 Barr Stock Options The Strike Price of those options is $45 For each option, you will get $66.50 minus $45.00 = $21.50 (your gain) Therefore, for 1,000 options, you will get $21.50 X 1,000
Slide 17: Process to Close
Process to Close Successful Close will Require Various Approvals Hart-Scott-Rodino in the United States Governments/Regulators in select other countries Barr Shareholders: November/December 2008: Proxy Shareholder vote From now through close both companies will operate separately Close expected by e
Slide 18: Overview of Teva
pry 4 | Overview of Teva lim! aay barr
Slide 19: Key Facts
Key Facts Direct presence in more than 60 countries Product distribution in 80+ countries 44 pharmaceutical manufacturing sites producing 50 billion doses 15 R&D centers 18 API manufacturing sites During 2007: 58% of sales in North America 25% in Western Europe (including Hungary) 17% in other regio
Slide 20: Teva Operations
Teva Operations Missouri Netherlands Hungary Italy India Israel Mexico Switzerland NJ Puerto Rico Czech Republic China Peru Chile Argentina Venezuela Toronto CA PA UK Brazil
Slide 21: Core Strengths in Generics
Core Strengths in Generics Broad product portfolio Largest first-to-file / Paragraph IV pipeline Technology: oral and semi solids, injectables, modified release, inhalants APIs/Vertical integration - approximately 250 compounds Intellectual property - over 1,000 patents Global supply chain
Slide 22: Market Position in Europe
Market Position in Europe Retail market position - selected markets UK Italy Netherlands Germany France Spain* Hungary Czech Poland Scandinavia* Belgium Market leader Not in top 10 In top 3 In top 10 Legend
Slide 23: Strong Brand Business
Strong Brand Business Copaxone(r): Largest product and its first major innovative drug, is a leading multiple sclerosis ("MS") therapy Azilect(r): Second significant innovative drug, indicated for the treatment of Parkinson's disease 5 projects in Phase III Clinical Studies Products in various devel
Slide 24: Strong Commitment to Biologics
Strong Commitment to Biologics G-CSF, interferon alpha 2b, and hGH (human growth hormone) sold in limited number of markets Manufacturing facilities located in Mexico, Hungary and China Bulk substance manufacturing facilities located in Lithuania and China CoGenesys' biotechnology research team, tec
Slide 25: Key Question: What does this mean for Barr employees?
Key Question: What does this mean for Barr employees?
Slide 26: For All Barr Employees
For All Barr Employees Business as usual throughout organization Continue to operate as separate companies until transaction closes Commitment to communicate throughout transaction process
Slide 27: Change of Control
"Change of Control" Acquisition would represent a "change of control" (i.e., ownership) Employee stock options and/or SARs Those granted prior to close will vest once Barr shareholders approve deal Barr 401 (k) and non-qualified plan company Matching contributions vest at closing ESPP Will continue
Slide 28: Our Expectations
Our Expectations Teva considers Barr employees a key asset of transaction Combination would create an even stronger global organization Barr's management team committed to working with Teva To ensure the new organization benefits from the expertise of Barr's global employee team To achieve a success
Slide 29: Our Expectations
Our Expectations We expect that Teva will seek to identify and cultivate talent from both organizations to Help achieve integration objectives Longer-term goals Teva will need to complete a detailed and objective review of the two businesses to determine Optimal organization structure Requirements f
Slide 30: Barr's Commitment
Throughout the process, we are committed to being a responsible employer If Barr employees lose their jobs as a result of the transaction, they will be eligible for a generous severance Barr US employees covered under collective bargaining unit: severance in accordance with collective agreement prov
Slide 31: Other Questions
Other Questions We have just announced the deal and have to work through many transition issues Too early to answer questions regarding: Synergy targets Management team Facilities/operations Benefits
Slide 32: Commitment to Communications
Commitment to Communications Communication program Conduct employee meetings on-site with key Barr executives Our promise - keep employees informed throughout the entire process Utilize facility meetings, HR Updates, Company-wide memos, department meetings, other appropriate communication tools Refe
Slide 33: Summary of Benefits
Summary of Benefits Combined Company will have: Annual revenues of approximately $11.9 billion 15.9% market share for all U.S. pharma companies 23.9% market share for all U.S. generic companies Operations in over 60 countries Leadership in the generic industry in number and success rate of patent ch
Slide 34: Questions and Answers
Questions and Answers July 18, 2008
Barr Pharmaceuticals — Merger or Acquisition (July 2008) on 6ix